RGNX REGENXBIO Inc.

39.98
+1.37  (+4%)
Previous Close 38.61
Open 38.74
Price To Book 2.98
Market Cap 1,471,529,147
Shares 36,806,632
Volume 127,376
Short Ratio
Av. Daily Volume 570,891

NewsSee all news

  1. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  2. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  3. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  4. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  5. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data due 2H 2019.
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1 trial ongoing.
RGX-111
Mucopolysaccharidosis Type I (MPS I)
Phase 1/2a data due at AAO October 11, 2019, 4:18 p.m. PT. Phase 2b trial to be initiated late 2019.
RGX-314
Wet age-related macular degeneration (wet AMD)
Phase 1/2 update due 2H 2019.
RGX-121
MPS II
Phase 2 trial to commence by the end of 2019.
RGX-314
Diabetic retinopathy

Latest News

  1. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  2. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  3. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  4. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  5. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  6. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  7. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  8. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  9. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  10. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  11. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  12. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  13. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  14. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  15. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  16. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  17. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  18. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  19. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  20. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  21. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  22. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  23. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  24. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  25. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  26. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  27. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  28. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  29. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  30. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  31. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  32. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  33. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  34. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  35. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  36. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  37. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  38. REGENXBIO to Present at Upcoming Investor Conferences

    ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary

  39. REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

    ROCKVILLE, Md., Aug. 27, 2019 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary